Clinical Trial

Canagliflozin Targeting Vascular Inflammation

Study acronym: CANTORSING
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-06-16; most recent amendment 2026-04-30.
Status change: Not Yet Recruiting → Recruiting 2024-12-05
Trial Details
NCT Number NCT05427084
Lead Sponsor Ottawa Heart Institute Research Corporation
Conditions Diabetes Type 2, Coronary Artery Disease
Enrollment 24 participants
Start Date 2024-11-15
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-06